Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

our and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

*Event rates are based
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... development and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... and the world's largest provider of surgical instruments to the Spine Industry. The ...
(Date:7/1/2015)... , ... July 01, 2015 , ... The next-generation sequencing ... key market segments, including the molecular diagnostics industry. BCC Research reveals in its new ... NGS-based tests, lower test costs, and a growing need for better diagnostics as part ...
(Date:7/1/2015)... Ariz. , July 1, 2015 Isagenix ... it has earned three Gold, three Silver, and three ... Awards gala held in Chicago ... as the premier business awards program in the U.S. ... recognizes our company,s strength in developing leaders, cultivating talent, ...
(Date:7/1/2015)... STRATFORD, CONNECTICUT (PRWEB) , ... July 01, 2015 ... ... disinfected or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have ... of medical devices now have an operator control device that will increase healthcare ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... announced,that they successfully reprogrammed adult cells back to ... treatments and,research without the need to clone human ... Senior Fellow in Bioethics,and author of Consumer,s Guide ... demonstrating that ethical science is also good science:,"Everyone ...
... Nov. 20 /PRNewswire-FirstCall/ - ARIUS Research Inc., ... the next wave of,antibody therapeutics, today announced ... Research, will present at the 14th Annual ... will present on,ARIUS, non-traditional approach to drug ...
... November 20 - Third quarter Consolidated Net ... Year; Third Quarter 2006 Results Adversely Affected by,Northern Hostilities ... the Issue of,Debentures Primarily for the Financing of the ... Standard and Poor,s Affiliation Oil Refineries Ltd. (TASE: ...
Cached Biology Technology:ARIUS to present at BioNorth Biotechnology and Life Sciences Conference 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 2Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 3Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 4Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 5Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 6Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 7Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 8Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 9Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 10Oil Refineries Announces Financial Results for Third Quarter and Nine Months 2007 11
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... , DETROIT Head and neck cancer outcomes associated with ... factors than biological differences, especially for African Americans, according to ... while those who self-reported to be African American are at ... between patients, genetic ancestry and cancer stage or survival. ...
... Boston, MA The 2010 Annual Meeting & OTO ... Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, ... 2010, in Boston, MA. Featuring more than 305 scientific ... for attendees, the annual meeting is a unique opportunity for ...
... a North Carolina State University researcher has shown that ... like solar cells to produce electricity. The findings prove ... mimic nature. They also have the potential to be ... standard-bearer: silicon-based solar cells. The bendable devices are ...
Cached Biology News:Genetic ancestry: A new look at racial disparities in head and neck cancer 22010 AAO-HNSF new research daily highlights: Sunday, Sept. 26, 2010 22010 AAO-HNSF new research daily highlights: Sunday, Sept. 26, 2010 32010 AAO-HNSF new research daily highlights: Sunday, Sept. 26, 2010 4Mimicking nature, water-based 'artificial leaf' produces electricity 2